NCCN Guidelines® Insights：卵巢癌/输卵管癌/原发性腹膜癌，3.2024 版。

IF 14.8 2区医学 Q1 ONCOLOGY

Journal of the National Comprehensive Cancer Network Pub Date : 2024-10-01 DOI:10.6004/jnccn.2024.0052

Joyce Liu, Andrew Berchuck, Floor J Backes, Joshua Cohen, Rachel Grisham, Charles A Leath, Lainie Martin, Daniela Matei, David S Miller, Sharon Robertson, Lisa Barroilhet, Shitanshu Uppal, Andrea Wahner Hendrickson, David M Gershenson, Heidi J Gray, Ardeshir Hakam, Angela Jain, Gottfried E Konecny, John Moroney, Elena Ratner, John Schorge, Premal H Thaker, Theresa L Werner, Emese Zsiros, Kian Behbakht, Lee-May Chen, Marie DeRosa, Eric L Eisenhauer, Gary Leiserowitz, Babak Litkouhi, Michael McHale, Sanja Percac-Lima, Kerry Rodabaugh, Roberto Vargas, Frankie Jones, Emily Kovach, Lisa Hang, Swathi Ramakrishnan, Ronald D Alvarez, Deborah K Armstrong

{"title":"NCCN Guidelines® Insights：卵巢癌/输卵管癌/原发性腹膜癌，3.2024 版。","authors":"Joyce Liu, Andrew Berchuck, Floor J Backes, Joshua Cohen, Rachel Grisham, Charles A Leath, Lainie Martin, Daniela Matei, David S Miller, Sharon Robertson, Lisa Barroilhet, Shitanshu Uppal, Andrea Wahner Hendrickson, David M Gershenson, Heidi J Gray, Ardeshir Hakam, Angela Jain, Gottfried E Konecny, John Moroney, Elena Ratner, John Schorge, Premal H Thaker, Theresa L Werner, Emese Zsiros, Kian Behbakht, Lee-May Chen, Marie DeRosa, Eric L Eisenhauer, Gary Leiserowitz, Babak Litkouhi, Michael McHale, Sanja Percac-Lima, Kerry Rodabaugh, Roberto Vargas, Frankie Jones, Emily Kovach, Lisa Hang, Swathi Ramakrishnan, Ronald D Alvarez, Deborah K Armstrong","doi":"10.6004/jnccn.2024.0052","DOIUrl":null,"url":null,"abstract":"The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.\",\"authors\":\"Joyce Liu, Andrew Berchuck, Floor J Backes, Joshua Cohen, Rachel Grisham, Charles A Leath, Lainie Martin, Daniela Matei, David S Miller, Sharon Robertson, Lisa Barroilhet, Shitanshu Uppal, Andrea Wahner Hendrickson, David M Gershenson, Heidi J Gray, Ardeshir Hakam, Angela Jain, Gottfried E Konecny, John Moroney, Elena Ratner, John Schorge, Premal H Thaker, Theresa L Werner, Emese Zsiros, Kian Behbakht, Lee-May Chen, Marie DeRosa, Eric L Eisenhauer, Gary Leiserowitz, Babak Litkouhi, Michael McHale, Sanja Percac-Lima, Kerry Rodabaugh, Roberto Vargas, Frankie Jones, Emily Kovach, Lisa Hang, Swathi Ramakrishnan, Ronald D Alvarez, Deborah K Armstrong\",\"doi\":\"10.6004/jnccn.2024.0052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.\",\"PeriodicalId\":17483,\"journal\":{\"name\":\"Journal of the National Comprehensive Cancer Network\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":14.8000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Comprehensive Cancer Network\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6004/jnccn.2024.0052\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2024.0052","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

NCCN 《卵巢癌/输卵管癌/原发性腹膜癌指南》为该疾病提供了多学科诊断、分期和治疗建议。这些 "NCCN 指南透视 "详细介绍了将 PARP 抑制剂作为卵巢癌维持治疗和单药治疗方案的演变如何为指南中的专家小组建议提供依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the National Comprehensive Cancer Network ONCOLOGY-

CiteScore

20.20

自引率

0.00%

发文量

388

审稿时长

4-8 weeks

期刊介绍： JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care. Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.